Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space... Show more
The Stochastic Oscillator for BNGO moved out of overbought territory on August 15, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 42 similar instances where the indicator exited the overbought zone. In of the 42 cases the stock moved lower. This puts the odds of a downward move at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNGO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BNGO's RSI Indicator exited the oversold zone, of 50 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 12, 2025. You may want to consider a long position or call options on BNGO as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BNGO just turned positive on August 13, 2025. Looking at past instances where BNGO's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BNGO advanced for three days, in of 222 cases, the price rose further within the following month. The odds of a continued upward trend are .
BNGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 100 cases where BNGO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.225) is normal, around the industry mean (10.930). P/E Ratio (0.026) is within average values for comparable stocks, (62.137). BNGO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.886). BNGO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (0.255) is also within normal values, averaging (39.773).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BNGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
a developer of technologies for analysis of large biological molecules
Industry PharmaceuticalsOther
A.I.dvisor indicates that over the last year, BNGO has been loosely correlated with MBOT. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if BNGO jumps, then MBOT could also see price increases.
Ticker / NAME | Correlation To BNGO | 1D Price Change % | ||
---|---|---|---|---|
BNGO | 100% | -5.30% | ||
MBOT - BNGO | 34% Loosely correlated | N/A | ||
CZMWY - BNGO | 31% Poorly correlated | +0.82% | ||
ARAY - BNGO | 30% Poorly correlated | -4.11% | ||
PACB - BNGO | 29% Poorly correlated | +6.50% | ||
SONVY - BNGO | 29% Poorly correlated | +0.21% | ||
More |
Ticker / NAME | Correlation To BNGO | 1D Price Change % |
---|---|---|
BNGO | 100% | -5.30% |
Pharmaceuticals: Other industry (105 stocks) | 20% Poorly correlated | -0.53% |
Pharmaceuticals industry (393 stocks) | 19% Poorly correlated | -1.05% |